Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases.

Matthew L ThomasGavin ShaddickRachel CharltonCharlotte CavillRichard HollandFlorenzo IannoneGiovanni LapadulaSimona LoprioreJakub ZávadaMichal UherKarel PavelkaLenka SzczukováProdromos SidiropoulosIrini FlouriAlexandros DrososBurkhard MöllerMichael J NissenRüdiger B MüllerAlmut SchererNeil J McHughAlison Nightingale

Published in: The Journal of rheumatology (2020)

Combination therapy of a TNFi with a csDMARD does not appear to affect improvement of disease activity or HAQ versus TNFi monotherapy, but it may improve TNFi drug survival.

Keyphrases

combination therapy
disease activity
rheumatoid arthritis
systemic lupus erythematosus
rheumatoid arthritis patients
ankylosing spondylitis
juvenile idiopathic arthritis
emergency department
clinical trial
smoking cessation
drug induced